Prostate cancers are usually not detected by Magnetic resonance imaging (MRI). However, a novel test called contrast-enhanced subharmonic imaging (SHI) can now help identify prostate cancer, reveals a new study.
SHI is a new technique for imaging of microbubble ultrasound contrast agents with improved suppression of background tissues.
Brachytherapy for Prostate Cancer
Learn about two different types of brachytherapy used for treating prostate cancer. Get information on the latest advances in the field.
Advertisement
‘Prostate cancer can be readily visible with the new technique called contrast-enhanced subharmonic imaging (SHI).’
Tweet it Now
The study was presented by Venkata Masarapu of Jefferson Medical College of Thomas Jefferson University at the ARRS 2018 Annual Meeting in Washington, DC.
The study was conducted to evaluate contrast enhanced SHI of the prostate for detection of prostate cancer.
![Decipher Test for Prostate Cancer]( "Decipher Test for Prostate Cancer")
Decipher test a genomic test for prostate cancer that determines the aggressiveness of the cancer and helps in planning the treatment course for the cancer.
Among the study group of 28 patients, contrast enhancement was clearly observed with color and power Doppler imaging, as well as with both harmonic imaging (HI) and SHI techniques in all subjects.
SHI provided improved contrast signal and tissue suppression relative to conventional HI.
Areas of increased vascularity were best delineated with maximum-intensity projection SHI, which allowed visualization of microvascular architecture.
This first in vivo application of contrast-enhanced SHI demonstrated contrast enhancement in the prostate of every study patient, with focal areas of contrast enhancement corresponding to sites of cancer in 18 percent of targeted biopsies, including five patients whose cancer was not identified by MRI.
The results indicate that SHI provides improved conspicuity of microbubble contrast enhancement and may improve the performance of contrast-enhanced ultrasound for detection of prostate cancer.
Source: Eurekalert
Decipher Test for Prostate Cancer
Decipher test a genomic test for prostate cancer that determines the aggressiveness of the cancer and helps in planning the treatment course for the cancer.
Advertisement
Among the study group of 28 patients, contrast enhancement was clearly observed with color and power Doppler imaging, as well as with both harmonic imaging (HI) and SHI techniques in all subjects.
SHI provided improved contrast signal and tissue suppression relative to conventional HI.
Areas of increased vascularity were best delineated with maximum-intensity projection SHI, which allowed visualization of microvascular architecture.
This first in vivo application of contrast-enhanced SHI demonstrated contrast enhancement in the prostate of every study patient, with focal areas of contrast enhancement corresponding to sites of cancer in 18 percent of targeted biopsies, including five patients whose cancer was not identified by MRI.
The results indicate that SHI provides improved conspicuity of microbubble contrast enhancement and may improve the performance of contrast-enhanced ultrasound for detection of prostate cancer.
Source: Eurekalert
Drugs for Prostate Cancer
Prostate cancer is the main cause of cancer death in men. One of the treatment method includes prescribing chemotherapeutic or hormonal drugs. These are prescribed depending on the type and stage of cancer.
Advertisement
 External Beam Radiation Therapy for Prostate CancerIn depth information about various types of external beam radiotherapy for treatment of prostate cancer. Radiotherapy is an alternative to surgical treatment such as radical prostatectomy. | Advertisement
|
Advertisement
Recommended Readings
![Prostate Specific Antigen [PSA]](https://www.medindia.net/images/patientinfo/120x100/prostate-specific-antigen.jpg "Prostate Specific Antigen [PSA]")
Latest Cancer News
The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.
A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.
Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.
Examining breast cancer occurrence and stages reveals disparities in urban versus rural rates, influenced by environmental conditions and the stage of the disease.
Polymerases theta and delta assist in the development of new cancer drugs known as polymerase theta inhibitors, currently undergoing clinical trials.